Kalium Chloratum Kabi (Potassium Chloride)

Potassium chloride dissociates into potassium ions and chloride in the bloodstream. The potassium ions are taken up by cells via the Na⁺/K⁺‑ATPase pump, restoring the extracellular potassium concentration needed for normal cardiac, muscular and neuronal electrical activity, thereby correcting electrolyte imbalance.

The prescribed dose of Kalium Chloratum Kabi is determined by the treating physician based on the patient’s current serum potassium level, clinical condition, renal function and the desired rate of correction. The healthcare professional calculates the required milliequivalents and sets the infusion rate accordingly.

Safety data for intravenous potassium chloride in pregnancy and lactation are limited. It should only be used when clearly needed and prescribed by a qualified clinician, weighing potential benefits against possible risks to the mother and fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Compared with oral potassium salts, the intravenous formulation of potassium chloride provides a rapid increase in serum potassium and is suitable for patients who cannot tolerate oral intake or need immediate correction. It differs from potassium phosphate or potassium gluconate in its chloride content and osmolarity, which may affect tolerability and infusion protocols.

Kalium Chloratum Kabi should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, inspect for particulate matter and ensure the vial is at room temperature if required for infusion.

The solution is administered intravenously, typically through a peripheral or central venous line. The infusion rate is set by the prescriber, often not exceeding 10 mEq per hour, and the patient is monitored with ECG and serum potassium measurements throughout the administration.

The most critical risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, and extravasation leading to tissue necrosis. Continuous cardiac monitoring and careful infusion rate control are essential to detect and mitigate these complications promptly.

Kalium Chloratum Kabi is contraindicated in patients with known hypersensitivity to potassium chloride, those with severe hyperkalemia, untreated digitalis toxicity, or significant renal impairment where potassium excretion is compromised, unless a specialist determines that benefits outweigh the risks.